Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomised controlled, non-inferiority and cost-effectiveness trial comparing polyhexanide and chlorhexidine with neomycin to mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation amongst adult hospital in-patients

Next Previous
X
Search
Trial Profile

A multi-centre, randomised controlled, non-inferiority and cost-effectiveness trial comparing polyhexanide and chlorhexidine with neomycin to mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation amongst adult hospital in-patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chlorhexidine (Primary) ; Mupirocin (Primary) ; Neomycin (Primary) ; Polihexanide (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Acronyms TIDE

    • Most Recent Events

    • 16 Oct 2023 Status changed from active, no longer recruiting to discontinued.
    • 04 Oct 2022 Status changed from recruiting to active, no longer recruiting.
    • 09 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top